EyePoint Stock

EyePoint Liabilities

The The Liabilities of EyePoint (EYPT) as of Sep 3, 2026 is 57.88 M USD. In the previous year, The Liabilities was 81.96 M USD — a change of -29.38% (lower).

Liabilities

57.88 MUSD

YoY

-29.38%

Last updated:

In 2026, EyePoint's total liabilities amounted to 57.88 M USD, a -29.38% difference from the 81.96 M USD total liabilities in the previous year.

The EyePoint Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
59.98 M USD
Jan 1, 2019
64.64 M USD
Jan 1, 2020
73.18 M USD
Jan 1, 2021
78.99 M USD
Jan 1, 2022
83.99 M USD
Jan 1, 2023
88.86 M USD
Jan 1, 2024
81.96 M USD
Jan 1, 2025
57.88 M USD
The EyePoint Liabilities history
YEARLiabilitiesYoY
57.88 MUSD-29.38%
81.96 MUSD-7.76%
88.86 MUSD+5.80%
83.99 MUSD+6.32%
78.99 MUSD+7.95%
73.18 MUSD+13.20%
64.64 MUSD+7.77%
59.98 MUSD+1,023.07%
5.34 MUSD-50.26%
10.74 MUSD+19.32%
9.00 MUSD+16.16%
7.75 MUSD
Access this data via the Eulerpool API

EyePoint Stock analysis

What does EyePoint do? EyePoint Pharmaceuticals Inc. is a biopharmaceutical company that specializes in the development and marketing of innovative products targeting medical and eye-related conditions. The company was founded in 1987 and is headquartered in Watertown, Massachusetts. EyePoint Pharmaceuticals has a diverse portfolio of products focused on the treatment of eye diseases. This includes products for the treatment of retinal diseases such as diabetic retinopathy, macular degeneration, and retinal vein occlusions, as well as products for preventing postoperative infections and relieving pain after eye surgeries. The business model of EyePoint Pharmaceuticals is based on the development and marketing of drugs and technologies tailored to the needs of patients and physicians in the field of ophthalmology. The company aims to improve patients' quality of life by offering innovative, safe, and effective products of the highest quality. One of EyePoint Pharmaceuticals' key technologies is the Durasert technology, which allows for controlled release of drugs over an extended period of time. This technology is utilized in many of the company's products, such as the Iluvien implant for treating diabetic retinopathy and macular degeneration. The company operates in various sectors, including ophthalmology, pain management, and ophthalmology. Each of these sectors has its own products and technologies tailored specifically to the needs of patients and physicians in those areas. A significant factor in EyePoint Pharmaceuticals' business model is partnerships with other companies and organizations that support collaboration in the development and marketing of new products. One such partnership is the joint venture with Ocumension Therapeutics, which aims to market EyePoint Pharmaceuticals' products in the Asian market. Overall, the company has introduced a variety of innovative products to the market that have had a significant impact on ophthalmology. These include products such as the Ozurdex implant for treating macular degeneration and uveitis, as well as the Dexycu injection for preventing postoperative inflammation and pain. In recent years, the company has made progress in the development of drugs for retinal diseases such as diabetic retinopathy and retinal vein occlusions. One such development is the Yutiq implant, specifically designed to slow the progression of diabetic retinopathy. Overall, EyePoint Pharmaceuticals has a significant influence on ophthalmology and plays a crucial role in the development of innovative products and technologies to improve patients' quality of life. The company will continue to play an important role in the medical industry by focusing on the development and marketing of products targeting specific needs of patients and physicians in the field of ophthalmology. EyePoint is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing EyePoint's Liabilities

EyePoint's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating EyePoint's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing EyePoint's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

EyePoint's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in EyePoint’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about EyePoint stock

The Liabilities of EyePoint is 57.88 M USD in 2026.

The Liabilities of EyePoint changed from 81.96 M USD to 57.88 M USD, representing a -29.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities EyePoint since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's EyePoint historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — EyePoint

All Key Metrics — EyePoint